Current Studies

The facts about participating in clinical research and our ongoing studies:

First and foremost your safety is our top priority. Participating in clinical research gives you access to the latest medical and scientific innovations in medicine as well as compensates the participant(s) for time and travel. Most importantly, you are advancing medical science by contributing to the development of vital new medicines and paving the way for these new medicines to reach the market.

Please let us know if you are interested in participating in a research study. Study participants receive medical care, lab tests, and study medication at no cost, and are compensated for their participation. Transportation can be provided.

For more information, please call: 954-366-0277.

 

CURRENTLY ENROLLING CLINICAL TRIALS

HOLLYWOOD NEUROLOGY
To participate or refer a patient, please call 954-366-0277.

Clinical Coordinators: Jorge Riveros, IMG, CCRC • Adriana Bohorquez, IMG, MPH, CCRC • Rebecca Nembhard, CCRC • Lucy Vargas, MA, CRC

Revance-ASPEN: Cervical Dystonia – A randomized double blind study with an injectable investigational medication for Isolated Cervical Dystonia.  After the initial treatment, patients can enter an Open Label Extension for 52 weeks.

Lilly-Periscope: Memory Loss/ALZHEIMER’S DISEASE – An 18 month double blind monthly IV study to evaluate the safety and efficacy of a tau antibody in patients 60-85 years of age with memory loss. Patients need a study partner to attend some visits.  MMSE 20-28

Lilly-Trailblazer: Memory Loss/ALZHEIMER’S DISEASE – 18 month double blind study to evaluate the safety and efficacy of an IV therapy in patients with memory loss 60-85 years of age. Patients need a study partner to attend some visits.  MMSE 20-28

Novartis-Generation 2: Memory Loss – A long term study to evaluate the effectiveness of an oral potential disease modifying therapy in patients 60-80 years of age, first part of screening is genotyping for Alzheimer’s disease.  MMSE 26-30 Patients need a study partner to attend some visits.

Charleston: Migraine – A single attack randomized placebo controlled study to evaluate the safety and efficacy of an oral combination drug for the acute treatment of a migraine with nausea.

Impax: Parkinson’s Disease – A Randomized controlled study to compare the safety and efficacy of an oral drug with Immediate Release-Carbidopa-Levodopa in Parkinson’s disease patients with motor fluctuations.

 

HOLLYWOOD PULMONARY
To participate or refer a patient, please call 954-366-0277.

Clinical Coordinator: Lucy Vargas, MA, CRC

No currently enrolling studies.

 

SUNRISE OFFICE NEUROLOGY
To participate or refer a patient Call 954-475-8171, ext 146 (Fanny) or ext 138 (Adriana)

Clinical Coordinators: Fanny Gully, CRC and Adriana Araujo, CRC

Roche – GRADUATE 2: Early Alzheimer’s Disease – 2 YEAR study to evaluate a potential disease modifying therapy, monthly subcutaneous injections versus placebo in patients between 50 and 90 years old with memory loss with 24 month open label extension. Patients need a study partner to attend some visits. (MMSE 22-28)

Lilly-Periscope: Memory Loss/ALZHEIMER’S DISEASE – An 18 month double blind monthly IV study to evaluate the safety and efficacy of a tau antibody in patients 60-85 years of age with memory loss. Patients need a study partner to attend some visits.  (MMSE 20-28)

Axsome: Migraine – Randomized, Double-blind, Single-dose, Placebo-controlled Study to Assess the Efficacy and Safety of AXS-07 (meloxicam and rizatriptan) for the Acute Treatment of Migraine in Adults.

Impax: Parkinson’s Disease – A Randomized controlled study to compare the safety and efficacy of an oral drug with Immediate Release-Carbidopa-Levodopa in Parkinson’s disease patients with motor fluctuations.

Acadia: Parkinson’s Disease w/Depression – An Open label 8-week study of safety and efficacy of Pimavaserin treatment in adults with Parkinson’s disease and Depression.

Prilenia: Parkinson’s Disease – Study to Assess the Efficacy and Safety of Two Doses of Pridopidine versus Placebo for the Treatment of Levodopa Induced Dyskinesia.

 

SUNRISE OFFICE NEUROLOGY – MS STUDIES
To participate or refer a patient –Call 954-475-8171 Ext 134 (Michele)

Clinical Coordinators: Michele Fistel, LPN, CCRC • Adriana Araujo,CCRC • Fanny Gully CRC

Biogen: NOVA – Relapsing-Remitting MS – A 72 week open label study for patients currently on Tysabri for at least 12 months, comparing 4 week dosing to 6 week dosing. Participants must be 18-60 years old.

Novartis: EXCHANGE – Advancing Relapsing-Remitting MS – A 6 month open label study for a new oral medication for MS, patients wanting to switch from taking beta-interferons, glatiramer acetate, fingolimod, dimethyl fumarate, or teriflunomide (must have been on these medications for at least 3 months). Patients must have had a relapse in the last 12 months. Extension study to follow, for patients completing the 6-month study. Participants must be between 18-65 years old.